

**Appl. No.** : 10/552,881  
**Filing Date** : July 17, 2006

### AMENDMENTS TO THE CLAIMS

1-35. **(Canceled)**

36. **(Currently amended)** A process for producing a cross-linked polysaccharide gel sufficiently cross-linked to resist degradation, comprising:

(a) contacting a polysaccharide mixed in an alkaline medium with a cross-linking agent consisting essentially of a bifunctional epoxide or a polyfunctional epoxide ~~cross-linker~~ to provide an essentially cross-linked polysaccharide wherein the ~~cross-linker~~ cross-linking agent is substantially linked to the polysaccharide by ether bonds;

(b) drying the cross-linked polysaccharide without substantially removing epoxide from the alkaline medium to form a cross-linked polysaccharide matrix; and

(c) neutralising the cross-linked polysaccharide matrix with an acidic medium to form a cross-linked polysaccharide gel ~~having a single type of cross-linkage,~~

wherein the cross-linked polysaccharide gel is sufficiently cross-linked by the cross-linking agent to resist degradation.

37. **(Previously presented)** The process according to claim 36 wherein the polysaccharide is hyaluronic acid, pectin, xanthan or alginic acid.

38. **(Previously presented)** The process according to claim 36 wherein the polysaccharide is selected from the group consisting of carboxymethyl dextran, hyaluronic acid, ~~or~~ carboxymethyl starch and an anionic derivative of carboxymethyl cellulose.

39. **(Previously presented)** The process according to claim 38 wherein the polysaccharide is hyaluronic acid.

40. **(Currently amended)** The process according to claim 36 wherein the ~~epoxide~~ cross-linking agent is 1,4 –butanediol diglycidyl ether, 1,2-ethanediol diglycidyl ether or an epoxy-substituted pentaerythritol.

41. **(Currently amended)** The process according to claim 40 wherein the ~~epoxide~~ cross-linking agent is 1,4 –butanediol diglycidyl ether.

**Appl. No.** : 10/552,881  
**Filing Date** : July 17, 2006

42. **(Previously presented)** The process according to claim 36 wherein the alkaline medium has a pH in the range of about 9 to 12.

43. **(Previously presented)** The process according to claim 42 wherein the alkaline medium comprises between 1 and 5 wt/vol percent polysaccharide and between 0.05 and 0.5 wt/vol percent epoxide.

44. **(Currently amended)** The process according to claim 43 wherein the epoxide cross-linking agent contacts the polysaccharide at a temperature of at least about 45°C.

45. **(Previously presented)** The process according to claim 44 wherein the cross-linked polysaccharide is dried under vacuum at a temperature of at least about 35°C.

46. **(Previously presented)** The process according to claim 36 wherein steps (a) and (b) are performed under alkaline conditions.

47. **(Previously presented)** The process according to claim 67 wherein the washing step comprises washing the cross-linked polysaccharide matrix with acetone.

48. **(Previously presented)** The process according to claim 47 wherein the neutralisation step (d) further comprises freeze drying the cross-linked polysaccharide gel and reconstituting the gel.

49. **(Previously presented)** The process according to claim 48 wherein the freeze dried cross-linked polysaccharide gel is reconstituted in phosphate buffered saline.

50. **(Previously presented)** The process according to claim 49 further comprising combining the polysaccharide with a biologically active substance.

51. **(Withdrawn)** A cross-linked polysaccharide gel substantially resistant to hyaluronidase degradation prepared by the process according to claim 36.

**Appl. No.** : 10/552,881  
**Filing Date** : July 17, 2006

52. **(Withdrawn)** The gel according to claim 51 wherein the gel releases less than about 75 percent uronic acid under hyaluronidase treatment.

53. **(Withdrawn)** The gel according to claim 51 wherein the gel releases no more than about 70 percent uronic acid under hyaluronidase treatment.

54. **(Withdrawn)** The gel according to claim 51 wherein the gel releases no more than about 65 percent uronic acid under hyaluronidase treatment.

55. **(Withdrawn)** The gel according to claim 51 wherein the gel releases less than about 75 percent uronic acid after being extruded or expelled from a 32 gauge needle.

56. **(Withdrawn)** The gel according to claim 51 wherein the gel releases no more than about 70 percent uronic acid after being extruded or expelled from a 30 gauge needle.

57. **(Withdrawn)** The gel according to claim 51 further comprising a biologically active substance.

58. **(Withdrawn)** The gel according to claim 57 wherein the biologically active substance is a hormone, cytokine, vaccine, cell, tissue augmenting substance, or mixture thereof.

59. **(Withdrawn)** The gel according to claim 58 wherein the tissue augmenting substance is collagen, starch, dextranomer, polylactide, poly-beta-hydroxybutyrate, or copolymers thereof.

60. **(Withdrawn)** The gel according to claim 57 wherein the biologically active substance is an alkaloid, peptide, phenothiazine, benzodiazepine, thioxanthene, hormone, vitamin, anticonvulsant, antipsychotic, antiemetic, anesthetic, hypnotic, anorexigenic, tranquilizer, muscle relaxant, coronary vasodilator, antineoplastic, antibiotic, antibacterial, antiviral, antimalarial, carbonic anhydrase inhibitor, nonsteroid antiinflammatory agent, vasoconstrictor, cholinergic agonist, cholinergic antagonist, adrenergic agonist, adrenergic antagonist narcotic antagonist or combination thereof.

**Appl. No.** : 10/552,881  
**Filing Date** : July 17, 2006

61. **(Withdrawn)** A pharmaceutical composition comprising:  
a cross-linked polysaccharide gel substantially resistant to hyaluronidase degradation prepared by the process according to claim 36;  
a biologically active substance; and  
a pharmaceutically acceptable carrier.
62. **(Withdrawn)** The pharmaceutical composition according to claim 61 wherein the preparation is in the form of a pill, tablet, capsule, suppository, spray, cream ointment or sticking plaster.
63. **(Withdrawn)** A method of treating or preventing a disorder or condition selected from the group consisting of tissue augmentation, arthritis, tissue adhesions, immunogenicity, diseases of the mucosa, dermatological conditions, ophthalmological conditions, hormonal conditions, joint lubrication conditions and cosmetic conditions, in a subject in need thereof, comprising administering a therapeutically effective amount of a gel substantially resistant to hyaluronidase degradation prepared by the process according to claim 36.
64. **(Withdrawn)** The method according to claim 63 wherein the gel further comprises a biologically active substance, and a pharmaceutically acceptable carrier.
65. **(Withdrawn)** The method according to claim 63, wherein the administration to the subject is by injection.
66. **(Withdrawn)** The method according to claim 63, wherein the administration to the subject is by topical application.
67. **(Previously presented)** The process according to claim 36, further comprising , between steps (b) and (c), washing the cross-linked polysaccharide matrix with a water miscible solvent.
68. **(Previously presented)** The process according to claim 67, wherein the washing step is performed under alkaline conditions.

**Appl. No.** : **10/552,881**  
**Filing Date** : **July 17, 2006**

69. **(Previously presented)** The process according to claim 39, wherein the cross-linked polysaccharide gel is substantially resistant to hyaluronidase degradation.

70. **(New)** The process according to claim 36, wherein the polysaccharide is contacted with one cross-linking agent